Added to YB: 2026-06-17
Pitch date: 2026-06-10
LAB.MC [bullish]
Labiana Health, S.A.
Author Info
No bio for this author
Company Info
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally.
Market Cap
EUR 55.4M
Pitch Price
N/A
Price Target
13.00
Dividend
N/A
EV/EBITDA
9.23
P/E
51.82
EV/Sales
1.21
Sector
Pharmaceuticals
Category
turnaround
The Cheapest CDMO in Europe. Double-Digit Growth. Expanding Margins. 8x Forward P/E. A Deep Dive and My Meeting with the Founder. - Labiana Health, S.A
LAB.MC: Spanish CDMO at 6.1x 2026E EBITDA (€14M), 22-41% discount to peers. Feb 2026 refinancing killed 16% predatory debt, saving €3-4M/yr interest, removed warrants/going concern. Rev €75M +13.5%, recurrent EBITDA tripled, 23% ROCE, own-brand mix lifting margins. Founder owns 54%. Net profit €2.6M→€7M by 2027. Risks: thin equity, €16k/day liquidity, single-country plants, Fosfo eroding. Target €13 (2027), €16 (2028)—double/triple.
Read full article (24 min)